Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Pediatrics, Clinical pharmacology, Pharmacokinetics, Physiology-based pharmacokinetic models, Extremely preterm, EXTREMELY PRETERM INFANTS, INTENSIVE-CARE, OUTCOMES, THERAPY, Humans, Infant, Infant, Newborn, Infant, Newborn, Diseases, Infant, Premature, Models, Biological, 1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine, 3215 Reproductive medicine, 4204 Midwifery

Abstract:

To truly attain effective and safe pharmacotherapy, the similarities and dissimilarities in physiology between micro-preemies and extreme preterm infants should be explored. The higher incidence of pulmonary hypertension and presence of adrenal insufficiency of prematurity in micro-preemies hereby serve as illustrations. The current limited data on pharmacokinetics, -dynamics and safety reflect the obvious need to collect such data, and to tailor modelling tools to their physiology and needs. Drug utilization hereby mirrors different needs and practices and may serve to guide prioritization decisions. Physiological data, combined with even limited observations on pharmacokinetics and -dynamics can be translated to effective modelling tools to attain effective and safe pharmacotherapy. We therefore discuss how valid research tools in pharmacology like physiology-based pharmacokinetic models can be developed, and how clinicians can contribute to such efforts, with the overarching aim to enable this shift from immature pharmacotherapy to pharmacotherapy for the immature.